Search British Business Bank
Popular Search placeholder

British Business Bank announces £5 million investment into Cyted Health

Press release 01 September 2025

The British Business Bank has announced a £5 million investment into Cyted Health, a leading gastrointestinal molecular diagnostics company, as part of an £32.5 million Series B funding round.

The round was led by the British Business Bank, EQT Life Sciences, and Advent Life Sciences, with continued support from existing investors Morningside and BGF. 

Founded by leading experts at the University of Cambridge, Cyted is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions. 

Cyted’s technology has already demonstrated significant success across the UK’s National Health Service, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications proving unmatched patient acceptability and real-world clinical impact. 

The financing will be used to accelerate the commercial expansion of Cyted’s diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests. 

Cyted’s existing platform consists of EndoSign®, an FDA 510(k)-cleared device enabling minimally invasive collection of esophageal cells, and advanced biomarker molecular testing for the detection of esophageal conditions. 

Marcel Gehrung, CEO and Co-founder of Cyted Health, said: 

This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier.

This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.

Science Minister Lord Vallance said:

I am pleased to see the British Business Bank back Cyted Health - a company whose growth demonstrates the ability of our universities to turn world-class life sciences research into successful commercial opportunities with the potential to improve people's lives.

Life sciences form a critical part of this Government's ambitions for both the economy and healthcare - and through our Life Sciences Sector Plan, we will continue to support the industry to even greater success.

Leandros Kalisperas, Chief Investment Officer at British Business Bank, said: 

Life sciences is an area of real opportunity for the UK.

We have an abundance of high potential, IP rich companies that can become market leaders if they have the funding needed to scale.

This is why life sciences is one of the eight key sectors included in the Government’s Industrial Strategy

The British Business Bank is already the most active investor in UK life sciences, but the sector will continue to be a priority for our investment to ensure companies like Cyted can grow and fulfil their potential.

Carmine Circelli, Director, Life Sciences at British Business Bank, said: 

Cyted is an excellent example of the kind of high-impact business we aim to back.

Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally.

Further information

Alex Knight, British Business Bank, [email protected]. 

Max Steward, MHP Communications, [email protected].

Notes to editors

About the British Business Bank

The British Business Bank is the UK government’s economic development bank. Established in November 2014, its mission is to drive sustainable growth and prosperity across the UK and to enable the transition to a net zero economy, by improving access to finance for smaller businesses. Its remit is to design, deliver and efficiently manage UK-wide smaller business access to finance programmes for the UK government.

The British Business Bank’s core programmes support £23bn 1  of finance to almost 64,000 2  smaller businesses.

As well as increasing the supply and diversity of finance for UK smaller businesses through its programmes, the Bank works to raise awareness of finance options available to smaller businesses. The British Business Bank's Business Guidance Library provides independent and impartial information to businesses about finance options, featuring short films, expert guides, checklists and articles from finance providers to help make their application a success. 

The British Business Bank is also responsible for administering the government’s three Coronavirus loan schemes and its Future Fund, together responsible for delivering £80.4bn in finance to 1.67m businesses. These schemes are now closed to new applications.

British Business Bank plc is a public limited company registered in England and Wales, registration number 08616013, registered office at Steel City House, West Street, Sheffield, S1 2GQ. It is a development bank wholly owned by HM Government. British Business Bank plc and its subsidiaries are not banking institutions and do not operate as such. With the exception of BBB Investment Services Limited they are not authorised or regulated by the Prudential Regulation Authority or the Financial Conduct Authority. BBB Investment Services Limited is authorised and regulated by the Financial Conduct Authority. A complete legal structure chart for the group can be found at british-business-bank.co.uk.

The Investment Programme is operated by British Business Investments Ltd, a wholly owned commercial subsidiary of British Business Bank plc. British Business Investments Ltd is registered in England and Wales with company number 09091930, and registered office at Steel City House, West Street, Sheffield, S1 2GQ. 

The transaction described above does not constitute or imply any endorsement, warranty or recommendation by the UK government, the British Business Bank plc, its subsidiaries or any other party of Beach Point Capital UK or its products or services.

About Cyted Health

Cyted Health is a gastrointestinal molecular diagnostics company dedicated to improving early detection and prevention of esophageal adenocarcinoma through innovative, minimally invasive diagnostics. The company has built a robust portfolio of peer-reviewed publications, conducted over 35,000 tests using its diagnostic platform, and is widely used across the National Health Service in the UK. Cyted Health is actively expanding its presence in the U.S. to bring its technology to more patients in need.

Latest news